Table 2.
Best overall response per investigator. Abbreviations: + = censored value; CI = confidence interval; IC = investigator’s choice; NR = not reached; ORR = objective resDonse rate.
| < 65 Years | ≥65 Years | |||
|---|---|---|---|---|
| Nivolumab (n = 172) | IC (n = 76) | Nivolumab (n = 68) | IC (n = 45) | |
| Best overall response, n (%) | ||||
| Complete response | 4 (2.3) | 0 | 3 (4.4) | 1 (2.2) |
| Partial response | 18 (10.5) | 5 (6.6) | 7 (10.3) | 1 (2.2) |
| Stable disease | 36 (20.9) | 31 (40.8) | 19 (27.9) | 12 (26.7) |
| Progressive disease | 72 (41.9) | 25 (32.9) | 27 (39.7) | 17 (37.8) |
| Unable to determine | 42 (24.4) | 15 (19.7) | 12 (17.6) | 14 (31.1) |
| ORR, n (%) | 22 (12.8) | 5 (6.6) | 10 (14.7) | 2 (4.4) |
| [95% CI] | [8.2–18.7] | [2.2–14.7] | [7.3–25.4] | [0.5–15.1] |
| Time to objective response among responders, median (range), mo | 2.1 (1.8–7.4) | 2.0 (1.9–2.0) | 2.1 (1.8–6.3) | 3.5 (2.3–4.6) |
| Duration of response among responders, median (range), mo | 8.5 (2.8 to 28.0+) | 3.0 (2.7+ to 11.3) | NR (2.8 to 32.8+) | 4.9 (1.5+to 4.9) |